Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Guardant Health And Quest Diagnostics Collaborate To Make Guardant's Shield Blood-Based Screening Test Available To Physicians And Patients Served By Quest In US

Author: Benzinga Newsdesk | September 24, 2025 07:19am

Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States.

Posted In: DGX GH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist